|Bid||362.00 x 1400|
|Ask||365.00 x 1400|
|Day's Range||357.28 - 362.33|
|52 Week Range||258.10 - 459.75|
|Beta (3Y Monthly)||1.47|
|PE Ratio (TTM)||75.30|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||435.10|
ShockWave has raised about $150 million in funding from investors who include Venrock, T. Rowe Price, Sectoral Asset Management, Sofinnova Capital and Fidelity.
Abiomed Inc NASDAQ/NGS:ABMDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ABMD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABMD. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABMD totaled $14.24 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NEW YORK, Feb. 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Interim data reported last month showed that 17 percent of patients who received the Impella RP survived 30 days, compared to 73 percent of patients in the company's earlier test, according to separate letters the FDA and Abiomed sent to physicians over the last week.
The Dow Jones Industrial Average added 0.70% to close at 25,239.37. The S&P 500 rose 0.68% to end at 2724.87, and the Nasdaq Composite surged 1.15% to close at 7347.54.
Abiomed (ABMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Abiomed earnings and sales beat estimates Thursday, prompting Abiomed stock to rise in midday action. The medical technology firm also said Europe approved its Impella Connect technology.
These baskets of stocks from Goldman Sachs have posted YTD 2019 gains nearly double that of the S&P 500. This is the first of 2 stories on them.
Abiomed (ABMD) delivered earnings and revenue surprises of 3.19% and -0.02%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Danvers, Massachusetts-based company said it had net income of 97 cents. The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...
Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.
Nokia's (NOK) revenues in the fourth quarter are likely to be hurt by strong seasonality and delays in project timing despite ramp up of 5G deliveries, particularly in North America.
QUALCOMM (QCOM) is expected to report lower year-over-year revenues in the fiscal first quarter, mainly due to continuity of nonpayment of royalties by Apple.